Year: 2014
Type: article
Abstract: Summary: The recognition that the tumor microenvironment contributes to tumor survival, growth, and response to therapy provides the rationale for considering it a therapeutic target. The article by Alspach and colleagues in this issue provides evidence that p38MAPK acts posttranscriptionally to promote the tumor-permissive secretory phenotype of both cancer-associated and senescent fibroblasts, and that p38MAPK inhibitors already in clinical trials have significant therapeutic potential. Cancer Discov; 4(6); 637–9. ©2014 AACR. See related article by Alspach et al., p. 716
Source: Cancer Discovery
Institutions: Institute of Cancer Research, New York University
Language: English
Topic: TGF-β signaling in diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2103845415